NYSE · Drug Manufacturers - General

BMY (BMY) Stock

$66.92 +0.16% NYSE: BMY Healthcare

Valuation

MetricValue
Price$66.92
Market Cap$136.70B
P/E Ratio14.88
P/B Ratio6.18
P/S Ratio2.81
EPS (TTM)$0.00
52-Week High$68.64
52-Week Low$42.52
Dividend Yield3.73%

Financials & Margins

MetricValue
ROE46.75%
ROA10.59%
ROCE20.16%
Gross Margin26.34%
Operating Margin26.34%
Net Margin18.87%
Debt/Equity1.93
Current Ratio1.26

Annual Financials (USD)

Metric20212022202320242025
Revenue$46.4B$46.2B$45.0B$48.3B$48.2B
Operating Profit$9.5B$9.3B$8.5B$9.7B$13.7B
Net Profit$7.0B$6.3B$8.0B$-8.9B$7.1B
EPS$3.12$2.95$3.86$-4.41$3.45
Op Margin20.6%20.1%18.8%20.0%28.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$109.3B$96.8B$95.2B$92.6B$90.0B
Total Liabilities$73.3B$65.7B$65.7B$76.2B$71.5B
Cash$14.0B$9.1B$11.5B$10.3B$10.2B
Borrowings$45.6B$40.7B$41.5B$51.2B$47.1B

Latest News

Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio? Zacks · Jul 14, 2026 Agilent Wins FDA Approval for PD-L1 Test to Guide Bristol Myers' Opdivo Use in GI Cancers MT Newswires · Jul 14, 2026 Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma Business Wire · Jul 14, 2026 Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb Motley Fool · Jul 14, 2026 Own Regeneron For Biotech Growth? Incyte Is Making Its Case. Trefis · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$16.2B$13.1B$13.9B$15.2B$14.2B
Investing Cash Flow$-1.5B$-2.2B$-3.5B$-22.6B$-5.4B
Financing Cash Flow$-5.6B$-7.0B$-5.1B$0$0
Net Cash Flow$-657.0M$-5.0B$2.2B$-1.2B$-137.0M
Free Cash Flow$15.2B$11.9B$12.7B$13.9B$12.8B

Valuation & Return Ratios

MetricValue
PEG Ratio0.18
EV / EBITDA10.34
FCF Yield8.29%
Quick Ratio1.38
Interest Coverage8.04
Return 1Y48.84%
Return 3Y22.00%
Return 5Y11.71%

Ownership

Insiders Held0.08%
Institutions Held83.77%
Institutions Float Held83.84%
Institutional HolderSharesReport Date
Blackrock Inc.171,682,8882026-03-31
Vanguard Capital Management LLC132,320,2402026-03-31
State Street Corporation98,564,9142026-03-31
JPMORGAN CHASE & CO92,475,1942026-03-31
Charles Schwab Investment Management, Inc.61,115,3732026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CI $283.06 +2.53% 11.58 $74.80B 2.22%
CVS $97.60 +3.93% 24.63 $124.53B 2.82%
ELV $403.04 +2.67% 17.89 $87.41B 1.71%
GSKGSK plc $51.58 9.28 $103.73B 3.49%
HCA $413.58 -0.21% 14.11 $89.54B 0.74%

About BMY

BMY is led by CEO Christopher S. Boerner, employs 34,100 people, headquartered in Princeton, US, publicly traded since 1972.

BMY stock trades at $66.92 with a market capitalization of $136.70B. The stock is valued at a price-to-earnings (P/E) ratio of 14.88, price-to-book of 6.18, price-to-sales of 2.81. Over the past 52 weeks the stock has ranged between $42.52 and $68.64, and currently trades 2.5% below its 52-week high. It pays a dividend yielding 3.73%.

On profitability, BMY generates a return on equity (ROE) of 46.75% — well above the market average, a sign of a high-quality business, return on capital employed of 20.16%, an operating margin of 26.34%, a net profit margin of 18.87%.

In its most recent fiscal year, BMY reported annual revenue of $48.2B, net profit of $7.1B, revenue has compounded at 2.5% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 1.93, a current ratio of 1.26, total assets of $90.0B, $10.2B in cash and equivalents.

BMY has an average daily trading volume of 11,547,525 shares, a beta of 0.23 (less volatile than the overall market).

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides